PAVmed (PAVM) AI Stock Analysis

• Market Cap: $9.27M
• Dividend Yield: N/A
• Average Volume (3M): 301.82K
• Price to Earnings (P/E): 0.4
• Beta (1Y): 1.31
• Revenue Growth: -73.36%
• EPS Growth: N/A
• Country: US
• Employees: 39
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): -0.74
• Shares Outstanding: 21,610,516
• 10 Day Avg. Volume: 352,742
• 30 Day Avg. Volume: 301,818
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 3.74
• Enterprise Value/Revenue: 4.94
• Enterprise Value/Gross Profit: -0.98
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $2.00
• Price Target Upside: 365.12% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 51 Neutral
• Price Target: $0.50 ▲(16.28% Upside)

PAVmed's overall stock score reflects significant financial challenges, despite some positive strategic initiatives and an attractive valuation. The company's ability to address profitability and liquidity issues will be crucial for future performance.

Positive Factors

Commercialization and Growth

Lucid Diagnostics reported strong EsoGuard testing results and is expected to receive Medicare coverage, which could drive further growth.

Partnerships and Collaborations

PAVM entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center to advance the Veris Health platform.

Valuation

The current valuation is attractive, representing significant upside from the current share price and balancing high risks with large upside opportunities.

Negative Factors

Revenue and Financial Performance

PAVM reported 2Q25 results with revenue below consensus and GAAP loss per share significantly wider than expectations.

Revenue Estimates

Revenue estimates for 2025 and 2026 have been lowered due to a slower expected ramp in patients.

Technology Integration

Technology integration challenges may delay patient enrollment and weigh on top-line growth through 2026.

PAVmed Business Overview & Revenue Model

Company Description

PAVmed Inc. is a diversified medical technology company focused on the development and commercialization of innovative medical devices and diagnostics. Operating primarily in the healthcare sector, PAVmed specializes in the creation of products that address unmet clinical needs across various medical fields, including gastroenterology, surgery, and cardiology. Its core products include the EsoCheck device for esophageal cell collection and the CarpX device for minimally invasive carpal tunnel release, among others.

How the Company Makes Money

PAVmed generates revenue through the sales of its medical devices and diagnostic products to hospitals, clinics, and healthcare providers. The company's revenue model is primarily based on direct sales and distribution agreements, allowing it to reach a wide range of customers. Key revenue streams include product sales from its innovative devices, potential licensing agreements, and partnerships with healthcare organizations that facilitate the adoption of its technologies. Additionally, PAVmed may benefit from reimbursement policies for its products, which can enhance sales and overall revenue growth.

PAVmed Financial Statement Overview

Summary

PAVmed faces significant financial challenges, particularly in terms of profitability and cash flow management. Despite revenue growth, the company struggles with negative margins and returns, indicating operational inefficiencies and potential liquidity risks.

Income Statement

PAVmed's income statement reveals significant challenges. The company has experienced substantial negative margins across all key metrics, including gross profit, net profit, EBIT, and EBITDA. Despite a notable revenue growth rate of 251.93% in the TTM period, the negative margins indicate severe profitability issues, with a net profit margin of -1885.26% and a gross profit margin of -5.06%. These figures suggest that the company is struggling to convert its revenue into profit, highlighting a critical need for operational improvements.

Balance Sheet

The balance sheet shows a mixed picture. While the debt-to-equity ratio is relatively low at 0.25, indicating manageable leverage, the return on equity is deeply negative at -140.79%, reflecting significant losses relative to shareholder equity. The equity ratio stands at 85.47%, suggesting a strong equity base relative to total assets. However, the negative ROE and historical equity deficits raise concerns about the company's ability to generate returns for shareholders.

Cash Flow

PAVmed's cash flow statement indicates some positive trends, such as a free cash flow growth rate of 72.83% in the TTM period. However, the operating cash flow to net income ratio is negative, and the free cash flow to net income ratio is slightly above 1, suggesting that the company is not effectively converting its net income into cash flow. The negative operating cash flow coverage ratio further underscores liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.01M	3.00M	2.45M	377.00K	500.00K	0.00
Gross Profit	-35.49M	-3.04M	-3.97M	-3.24M	-85.00K	-23.00K
EBITDA	-4.63B	29.67M	-75.74M	-99.41M	-55.90M	-35.81M
Net Income	72.88M	39.79M	-64.17M	-88.98M	-50.35M	-34.33M
Balance Sheet
Total Assets	43.89M	30.66M	33.12M	53.98M	86.98M	19.78M
Cash, Cash Equivalents and Short-Term Investments	4.00B	1.19M	19.64M	39.74M	77.26M	17.26M
Total Debt	9.31B	31.86M	48.73M	36.64M	0.00	14.96M
Total Liabilities	12.47M	37.69M	57.14M	43.05M	7.56M	20.25M
Stockholders Equity	40.79M	-2.50M	-53.83M	-9.68M	61.67M	1.90M
Cash Flow
Free Cash Flow	-2.77B	-33.61M	-52.28M	-72.53M	-42.06M	-21.97M
Operating Cash Flow	-2.77B	-33.55M	-52.04M	-70.98M	-40.59M	-21.91M
Investing Cash Flow	-24.14M	-16.18M	758.00K	-4.74M	-3.72M	-55.00K
Financing Cash Flow	2.49B	31.28M	31.17M	38.21M	104.31M	33.01M

PAVmed Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAVM, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.45, below the 50-day MA of 0.52, and below the 200-day MA of 0.66, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 40.75 is Neutral, neither overbought nor oversold. The STOCH value of 16.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAVM.

PAVmed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%
PAVM	51 Neutral	$9.27M	0.37	-499.57%	―	-73.36%	―
SSKN	47 Neutral	$9.17M	―	-235.41%	―	0.36%	-17.20%
TNON	47 Neutral	$10.39M	―	-335.48%	―	-12.60%	95.87%
HSCS	47 Neutral	$7.46M	―	-233.04%	―	-76.61%	73.25%
CODX	45 Neutral	$11.96M	―	-63.40%	―	-91.14%	9.47%
BMRA	40 Underperform	$8.19M	―	-92.99%	―	-1.88%	23.99%

PAVmed Corporate Events

PAVmed Reports Q2 2025 Financial Results and Developments

In its second quarter of 2025, PAVmed Inc. reported significant business developments and financial results. Lucid Diagnostics processed 2,756 EsoGuard tests, generating $1.2 million in revenue, and secured a Medicare LCD meeting for September 4, 2025. Veris Health completed financing and is advancing its implantable monitor towards FDA clearance, with strategic partnerships in place to enhance its commercial deployment. PAVmed’s financial results showed a GAAP net loss of $13.3 million, with a strengthened balance sheet and cash reserves of $4.0 million as of June 30, 2025.

PAVmed Granted Nasdaq Extension for Compliance

On July 29, 2025, PAVmed Inc. received a notification from Nasdaq granting an additional 180 days, until January 19, 2026, to comply with the minimum bid price requirement of $1 per share. The company had initially been given until July 22, 2025, to meet this requirement but failed to do so. Despite this, Nasdaq has allowed an extension, and PAVmed plans to explore all options to regain compliance. The company’s stock will continue to trade under the symbol ‘PAVM’ without interruption.

PAVmed’s Veris Health Completes $2.5M Offering

On June 23, 2025, Veris Health Inc., a subsidiary of PAVmed Inc., completed a $2.5 million offering by selling shares and warrants to accredited investors, aimed at funding the development of its implantable physiological monitor and general operations. This strategic move enhances Veris’ financial position and provides investors with future participation rights, potentially strengthening its market presence and operational capabilities.

PAVmed Holds Annual Stockholders Meeting, Approves Key Proposals

On June 18, 2025, PAVmed Inc. held its annual meeting of stockholders, where approximately 77.2% of shares were represented. During the meeting, stockholders elected management’s nominees for director, approved the issuance of common stock upon exercise of pre-funded warrants, amended the 2014 Long-Term Incentive Equity Plan to increase available shares, approved executive compensation, and ratified the appointment of Marcum LLP as the independent registered certified public accounting firm for 2025.